Detalhe da pesquisa
1.
Richter transformation: epigenetics to blame?
Blood;
141(24): 2915-2917, 2023 06 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37318906
2.
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1.
Haematologica;
105(10): 2440-2447, 2020 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33054084
3.
Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations.
Blood;
139(22): 3340-3344, 2022 06 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35377939
4.
From Biology to Therapy: The CLL Success Story.
Hemasphere;
3(2): e175, 2019 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31723816
5.
Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell lines.
Leuk Res;
38(1): 49-56, 2014 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24225136
6.
Interleukin-6, osteopontin and Raf/MEK/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholines.
Leuk Res;
36(6): 764-72, 2012 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22421411
7.
A particular expression pattern of CD13 epitope 7H5 in chronic lymphocytic leukaemia--a possible new therapeutic target.
Hematology;
17(3): 132-9, 2012 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22664111
8.
Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity.
Cancer Chemother Pharmacol;
67(1): 13-25, 2011 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20177898
9.
Erucylphospho-N,N,N-trimethylpropylammonium shows substantial cytotoxicity in multiple myeloma cells.
Ann N Y Acad Sci;
1171: 350-8, 2009 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19723075
10.
The expression level of the tumor suppressor retinoblastoma protein (Rb) influences the antileukemic efficacy of erucylphospho-N,N,N-trimethylpropylammonium (ErPC3).
Cancer Biol Ther;
6(6): 930-5, 2007 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17495525